

# ACTIVITY REPORT

For the fourth quarter  
of 2024



**TCHAIKAPHARMA**  
**HIGH QUALITY MEDICINES**

TCHAIKAPHARMA HIGH QUALITY MEDICINES INC.

23.01.2025

## **General information about Tchaikapharma High Quality Medicines Inc.**

### **History and development of Tchaikapharma High Quality Medicines Inc.**

#### **Legal and commercial name**

The legal and commercial name of the company is Tchaikapharma High Quality Medicines Inc.

#### **Location and registration. Unique Identification Code (UIC)**

The Company was listed in the Commercial Registry by Decision from 14.03.2000 on the company case 1096/2000 of the Varna District Court as a joint stock company named TCHAIKA PHARMA INC.

By decision of the General Meeting of Shareholders from 04.07.2003, entered by Decision from 30.07.2003 on the company case 1096/2000 of the Varna District Court, the name was changed to TCHAIKAPHARMA HIGH QUALITY MEDICINES INC.

The Company is listed in the Commercial Register of the Registry Agency at the Ministry of Justice with **UIC 103524525**. With registered office. 1 G. M. Dimitrov Bld .

#### **Foundation date and duration in time**

The Company was founded and entered in the Commercial Registry by Decision from 14.03.2000 on the company case 1096/2000 of the Varna District Court as a joint stock company. The duration of the Company is not limited in time.

#### **Country of Company registration, headquarters and address pursuant to the Statute; legal form; legislation under which the Company operates**

Tchaikapharma High Quality Medicines Inc. is a joint stock company which operates in compliance with the legislation of the Republic of Bulgaria.

The Company was incorporated in the Republic of Bulgaria.

The headquarters and registered office of the Company:

Republic of Bulgaria, 1172 Sofia, 1 G.M. Dimitrov Blvd.

Contact Address: 1172 Sofia, 1 G.M. Dimitrov Blvd.

Telephone: (359 2) 402 64 82

Internet site: [www.tchaikapharma.com](http://www.tchaikapharma.com)

#### **Important events in the development of the business of the Company**

Important events in the development of the Issuer for the last three years:

- Tchaikapharma High Quality Medicines Inc. was not transformed.
- Tchaikapharma High Quality Medicines Inc. was not transferred or pledged.
- There were no significant changes in the scope of activity of Tchaikapharma High Quality Medicines Inc.
- There were no filed claims for opening of insolvency proceedings.
- By Decision of the General Assembly of 20.06.2022 the profit of 2021 in the amount of BGN 1,399,422.40. (One million three hundred and ninety-nine thousand four hundred and twenty-two leva and 24 st.) shall be allocated as follows BGN 139,942.22 (One Hundred and thirty nine thousand nine hundred and forty two levs and 22 sts.) to be allocated to reserves and BGN 1,259,480.02 (One million two hundred and fifty nine thousand four hundred and eighty levs and 02 sts.) to be allocated to Retained Earnings.
- By Decision of the General Assembly of 20.06.2023 the profit of 2022 in the amount of BGN 2,791,019.53. (Two million seven hundred and ninety-one thousand nineteen leva and 53 st.) shall be allocated as follows BGN 271,101.95 (Two hundred and seventy one thousand one hundred and one levs and 95 sts.) to be allocated to reserves and BGN 2,499,194.65 (Two million four hundred and ninety nine thousand one hundred and ninety four levs and 65 sts.) to be allocated to Retained Earnings.
- By Decision of the General Assembly of 25.06.2024 the accumulated retained profit in the amount of BGN 7,707,502.56 (Seven million seven hundred and seven thousand five hundred and two levs and 56 st.) shall be distributed as follows: BGN 7,300,000 (Seven million and three hundred thousand levs) shall go for capital increase, reserves shall be set aside BGN 339,950.56 (Three hundred and thirty-nine thousand and nine hundred and fifty levs and 56 st.) and additional reserves BGN 7,552.30 (Seven thousand five hundred and fifty-two leva and 30 st.), BGN 60,000 (Sixty thousand leva) remains retained earnings.
- The current capital of the Company is BGN 91,800,000 distributed in 91,800,000 ordinary dematerialized voting shares with a par value of BGN 1 (one) each.

Tchaikapharma High Quality Medicines Inc. is one of the fastest growing Bulgarian company specialized in manufacturing high quality and affordable generic and original medicines. The production facilities of the company are built in accordance with European requirements. The company is focused of quality and safety of the production of medicinal products for human medicine. In the years in which the company has been on the market it has proved its honesty and patient care.

Its main goal is the renewal of current trends in the worldwide drug therapy. The main priority for the company are medicinal products for the treatment of diabetes, diseases of the central nervous system, cancers and it is mainly focused on medications associated with the treatment of cardiovascular diseases.

## Investments

**Major investments for each of the following financial years: 2022, 2023 and 2024.**

Overview of the investments in fixed assets by type and year is presented in the following table.

| <b>Investments for the period</b>  | <b>2022</b>  | <b>2023</b>  | <b>2024</b> |
|--|--------------|--------------|-------------|
| <b>Tchaikapharma High Quality Medicines Inc.</b>                           |              |              |             |
| <b>I. Fixed tangible assets</b>  | <b>4 630</b> | <b>964</b>   | <b>658</b>  |
| 1. Land and buildings  |              |              | 158         |
| 2. Property and equipment  | 4 596        | 957          | 355         |
| 3. Other fixed assets  | 34           | 7            | 145         |
| <b>II. Fixed intangible assets</b>   | <b>375</b>   | <b>417</b>   | <b>86</b>   |
| 1. Industrial property rights  | 307          | 417          | 47          |
| 2. Software  | 49           |              | 39          |
| 3. Patents and licenses  | 19           |              |             |
| <b>Total amount of acquisition of fixed tangible and intangible assets</b> | <b>5 005</b> | <b>1 381</b> | <b>744</b>  |

## Major investments in progress

The company invested in the purchase of a machine for visual control of each vial in order to optimize the production process and faster release of the finished product. Installation at the Varna plant is complete and the machine is now in operation.

## Economic activity

The entered in the Commercial Register activity of the Company is: purchase of substances and formulations for the production and sale of pharmaceuticals in finished or processed form, (after Marketing Authorisation); primary and secondary packaging of formulations (after Marketing Authorisation); import, export, re-export and merchandising in original or processed form; barter transactions and commissions; commercial representation of foreign and domestic individuals and legal entities at home and abroad; industrial and commercial management; consulting, marketing, brokerage, leasing, licensing, entrepreneurship, transport and shipping, research and development activities.

Currently the main scope of activity of the Company can be summarized as follows:

- Production
- Packaging (primary and secondary)
- Marketing and promotion of medicines
- Research and Development

Tchaikapharma High Quality Medicines Inc. continuously maintains its production facilities in accordance with the contemporary European requirements for Good Manufacturing Practice in the production of medicines. At present, more than 150 medicinal products are produced in the company's factories. The premises and the equipment of the factories are executed in full compliance with the European requirements for the production of medicines and for the plant in Varna – also for sterile medicinal products.

### **Submitted documentation to BDA (Bulgarian Drug Agency):**

#### **Submitted applications for MA for new products:**

Febuxostad - Tchaikapharma 80 mg film-coated tablets; 120 mg film-coated tablets - IAL-46928/29.10.2024; IAL-46929/29.10.2024

Tadalafil-Tchaikapharma 5 mg; 10 mg; 20 mg film-coated tablets - IAL-53718/10-12-2024; IAL-53720/10-12-2024; IAL-53721/10-12-2024

#### **Submitted Renewals:**

Reverantza 20 mg/5 mg film-coated tablets - IAL-29116/02-07-2024

Reverantza 40 mg/5 mg film-coated tablets - IAL-29116/02-07-2024

#### **Submitted variations:**

Tamayra 5 mg/5 mg; 10 mg/5 mg hard capsules - Type IB - IAL-50633/21-11-2024

Levor 5 mg/ml solution for infusion - Type IB - IAL-53728/10-12-2024

Levor 500 mg film-coated tablets - Type IB - IAL-53726/10-12-2024

Vorifungal 200 mg powder for solution for infusion - Type IB - IAL-53725/10-12-2024

Levor 500 mg film-coated tablets - Type IB - IAL-54439/13-12-2024

Verapamil-Tchaikapharma 80 mg coated tablets; 240 mg prolonged-release tablets - group IB; IB; IA - IAL-55235/18-12-2024

Kefadim 1g powder for solution for injection – TypeIA - IAL-43377/04-10-2024

ToraFlora 5 mg; 10 mg tablets - notif. Art 61 (3) - IAL-43373/04-10-2024

Prostanorm 6 mg/0,4 mg modified-release tablets - notif. Art 61 (3) - IAL-43369/04-10-2024

Fluidoro 10 mg film-coated tablets – Type II - IAL-43571/07-10-2024

Ceftriaxon-Tchaikapharma 2 g powder for solution for injection/infusion – Type IA - IAL-50474/20-11-2024

Ceftriaxon-Tchaikapharma 1 g powder for solution for injection/infusion – Type IA - IAL-50473/20-11-2024

Amarhyton 50 mg; 100 mg; 150 mg prolonged-release capsules, hard – Type IA - IAL-50046/18-11-2024

Akinestat 2 mg tablets - group IAin; Iain - IAL-50050/18-11-2024

Sinepar 200 mg/50 mg prolonged-release tablets – Type IA - IAL-50065/18-11-2024

Zornichka 25 mg tablets - group IB; IA - IAL-50059/18-11-2024

**Total: 16**

**Approved MA's from BDA:**

**Approved MA's for new products:**

Reducci (lercanidipine) 10 mg film-coated tablets - BG/MA/MP-67115/18.11.2024

Reducci (lercanidipine) 20 mg film-coated tablets - BG/MA/MP-67116/18.11.2024

**Approved Renewals:**

**Approved variations:**

Fluidoro 10 mg film-coated tablet - group var IA;IAin;IA - IAL-42677/01-10-2024

Kefadim 1g powder for solution for injection - Type IA - BG/MA/MP-66883/23-10-2024

CentroQueen 100 mg; 200 mg film-coated tablets - notif. Art 61 (3) - IAL-45160/16-10-2024

Pisizif SR 1,5 mg prolonged release tablets - notif. Art 61 (3) - IAL-45163/16-10-2024

Nordipine 5 mg; 10 mg tablets - notif. Art 61 (3) - IAL-45166/16-10-2024

Tamayra Plus 5mg/5mg/12,5mg; 5mg/5mg/25mg; 10mg/5mg/25mg - Type Iain - IAL-44610/14-10-2024

Diclofenac-Tchaikapharma 50 mg gastro-resistant tablets - Type IB - BG/MA/MP-66887/23-10-2024

Remifentanil-Tchaikapharma 5 mg sol. For injection/infusion - Type IA - IAL-44643/14-10-2024

Methylprednisolone-Tchaikapharma 40 mg powder and solvent for solution for injection - Type Iain - BG/MA/MP-66773/11-10-2024

ToraFlora 5 mg; 10 mg tablets - notif. Art 61 (3) - IAL-47229/01-11-2024; IAL47726/01-11-2024

Prostanorm 6 mg/0,4 mg modified-release tablets - notif. Art 61 (3) - IAL-47918/04-11-2024

Akinestat 2 mg tablets - notif. Art 61 (3) - IAL-47900/04-11-2024

Cardifriend-Co 5 mg/12,5 mg tablets - notif. Art 61 (3) - IAL-47896/04-11-2024

Bravylol 5 mg tablets - notif. Art 61 (3) - IAL-47907/04-11-2024

Klacar 500 mg film-coated tablets - group IA;IA - IAL-47854/04.11.2024

Amarhyton 50 mg; 100 mg; 150 mg prolonged-release capsules, hard - notif. Art 61 (3) - IAL-48235/05-11-2024; IAL-48242/05-11-2024; IAL-48217/05-11-2024

PlaquEx 75 mg film-coated tablets - notif. Art 61 (3) - IAL-48218/05-11-2024

Alonet 400 mg film-coated tablets - notif. Art 61 (3) - IAL-48221/05-11-2024

Fluidoro 10 mg film-coated tablets - Type II - IAL-50224/18-11-2024

Irbesso 150 mg; 300 mg film-coated tablets - notif. Art 61 (3) - IAL-48363/06-11-2024; IAL-48339/06-11-2024

Clopasa 0,5 mg tablets - notif. Art 61 (3) - IAL-47893/04-11-2024

Metformin-Tchaikapharma 850 mg film-coated tablets - notif. Art 61 (3) - IAL-47876/04-11-2024

Pretimectal 35 mg modified-release tablets - notif. Art 61 (3) - IAL-47733/01-11-2024

Betablockade 50 mg prolonged-release tablets - notif. Art 61 (3) - IAL-47880/04-11-2024

Ceftriaxon-Tchaikapharma 2 g powder for solution for injection/infusion - Type IA - IAL-53086/05-12-2024

Ceftriaxon-Tchaikapharma 1 g powder for solution for injection/infusion - Type IA - IAL-53086/05-12-2024

Amarhyton 50 mg; 100 mg; 150 mg prolonged-release capsules, hard - Type IA - IAL-52614/03-12-2024;

IAL-52615/03-12-2024; IAL-52616/03-12-2024

Sinepar 200 mg/50 mg prolonged-release tablets - Type IA - IAL-53697/10-12-2024

Zornichka 25 mg tablets - group IB; IA - IAL-50059/13-12-2024

**Total: 29**

## Kosovo

### Submitted applications of MA's for new products:

### Approved MA's for new products:

### Submitted Renewals:

PlaquEx 75 mg film-coated tablets

Irbesso 150 mg film-coated tablets

Irbesso 300 mg film-coated tablets

### Approved Renewals:

### Submitted variations:

### Approved variations:

Irbesso 150 mg; 300 mg film-coated tablets – grouped variation type II – 12.11.2024

### Employees

As of 31.12.2024 the average number of employees in Tchaikapharma High Quality Medicines Inc. was 207 (191 as of 31.12.2023). In the table below detailed information about the employees in the company is provided

|   | <b>31.12.2024</b> | <b>Share</b> |
|---|-------------------|--------------|
| <b>Number of employees as of 31.12.2024</b> | <b>207</b>        | <b>100%</b>  |
| Higher education                            | 131               | 63%          |
| Secondary education                         | 74                | 36%          |
| Primary education                           | 2                 | 1%           |
| Employees under 30 years                    | 73                | 35%          |
| Employees 31 - 40 years                     | 75                | 36%          |
| Employees 41 - 50 years.                    | 49                | 24%          |
| Employees 51 - 60 years.                    | 10                | 5%           |
| Employees 60+ years                         | 0                 | 0%           |
| Women                                       | 99                | 48%          |
| Men   | 108               | 52%          |

### Significant events since the beginning of the year until 31.12.2024

In the fourth quarter of 2024 there were no significant events.



## Key financial indicators

| Indicators  | 01-12/2024<br><i>BGN '000</i> | 01-12/2023<br><i>BGN '000</i> | Change<br>% |
|---|-------------------------------|-------------------------------|-------------|
| Sales revenue   | 53 141                        | 48 512                        | 9.54%       |
| Earnings before interest, taxes and depreciation (EBITDA) | 8 242                         | 6 766                         | 21.81%      |
| Net profit  | 5 038                         | 3 400                         | 48.17%      |
| Indicators  | 01-12/2024<br><i>BGN '000</i> | 01-12/2023<br><i>BGN '000</i> | Change<br>% |
| Non-current assets  | 42 364                        | 41 640                        | 1.74%       |
| Current assets  | 84 420                        | 80 865                        | 4.40%       |
| Equity  | 126 784                       | 122 505                       | 3.50%       |
| Non-current liabilities                                   | 2 228                         | 2 189                         | 1.78%       |
| Current liabilities                                       | 14 511                        | 15 309                        | -5.21%      |
|   | 01-12/2024                    | 01-12/2023                    |             |
| EBITDA/Sales revenue                                      | 16%                           | 14%                           |             |
| Net profit/Sales revenue                                  | 9%                            | 7%                            |             |

## Review of the risk factors

- The Company's activities could be affected by any change in the regulatory requirements for the production of pharmaceutical products.
- Changes to the legislation regulating the Company's business are possible, and these can potentially increase the costs of compliance or have another effect on its operations.
- The production processes of the Company are subject to stringent requirements and approvals by regulatory authorities which may delay or interrupt the operations of the Company.
- The ability of the Company to pay dividends depends on a number of factors and there is no guarantee that in a year it will be able to pay dividends in accordance with its dividend policy.
- The Company is exposed to operational risk, which is inherent in its business activities.
- The Company is subject to multitude laws and regulations in the field of environmental protection and health and safety conditions and is exposed to potential liabilities related to the environment.
- The Company is exposed to strong competition.
- The Company operates in active exchange with foreign suppliers and customers. It is therefore exposed to currency risk, mainly against the US dollar. Currency risk is related to the adverse movement in the exchange rate of the US dollar against the Bulgarian lev in future business operations, recognized foreign currency assets and liabilities. The rest of the company's operations are usually denominated in Bulgarian lev and/or in euros.

## Sales by types of dosage forms

| <b>Revenue by dosage forms</b> | <b>01-12/2024</b> | <b>01-12/2023</b> |
|--------------------------------|-------------------|-------------------|
|                                | <i>BGN '000</i>   | <i>BGN '000</i>   |
| Tablets                        | 43 981            | 42 635            |
| Ampules                        | 5 434             | 655               |
| Vials                          | 3 582             | 5 154             |
| <b>Total:</b>                  | <b>52 997</b>     | <b>48 444</b>     |

| <b>Revenue by therapeutic groups</b>         | <b>01-12/2024</b> | <b>01-12/2023</b> |
|--|-------------------|-------------------|
|  | <i>BGN '000</i>   | <i>BGN '000</i>   |
| Cardiovascular system                        | 34 637            | 34 516            |
| Musculoskeletal system and connective tissue | 49                | 50                |
| Respiratory system and antibiotics           | 6 223             | 3 802             |
| Nervous system                               | 1 104             | 1 827             |
| Endocrine system                             | 4 252             | 4 172             |
| Other products                               | 4 032             | 1 876             |
| Digestive system and metabolism              | 2 432             | 1 950             |
| Food supplements                             | 31                |                   |
| Oncology                                     | 238               | 252               |
| <b>Total:</b>                                | <b>52 997</b>     | <b>48 444</b>     |

|  |           |            |
|--|-----------|------------|
| <b>Changes in the inventories of products and work in progress</b> | <b>79</b> | <b>233</b> |
|--|-----------|------------|

| <b>Other operating income</b> | <b>01-12/2024</b> | <b>01-12/2023</b> |
|-------------------------------|-------------------|-------------------|
|                               | <i>BGN '000</i>   | <i>BGN '000</i>   |
| Income from rent              | 66                | 63                |
| Other income                  | 309               | 72                |
| <b>Total:</b>                 | <b>375</b>        | <b>135</b>        |

| <b>Financial income</b>               | <b>01-12/2024</b> | <b>01-12/2023</b> |
|---------------------------------------|-------------------|-------------------|
|                                       | <i>BGN '000</i>   | <i>BGN '000</i>   |
| Income from interest                  | 478               | 462               |
| Income from exchange rate differences | 52                | 75                |
| <b>Total:</b>                         | <b>530</b>        | <b>537</b>        |

## Core activity expenses

| <b>Operating expenses</b>   | <b>01-12/2024</b> | <b>01-12/2023</b> |
|-----------------------------|-------------------|-------------------|
|                             | <i>BGN '000</i>   | <i>BGN '000</i>   |
| Book value of sold products | 2 251             | 862               |
| Materials                   | 13 543            | 12 172            |
| External services           | 19 515            | 20 269            |

|                       |               |               |
|-----------------------|---------------|---------------|
| Salaries              | 7 649         | 6 198         |
| Social security costs | 1 438         | 1 135         |
| Depreciation costs    | 2 519         | 2 809         |
| Other                 | 528           | 899           |
| <b>Total:</b>         | <b>47 443</b> | <b>44 344</b> |

| <b>Cost of materials</b>             | <b>01-12/2024</b> | <b>01-12/2023</b> |
|--------------------------------------|-------------------|-------------------|
|                                      | <i>BGN '000</i>   | <i>BGN '000</i>   |
| Basic material                       | 12 064            | 10 731            |
| Electricity                          | 796               | 804               |
| Fuels and lubricants                 | 147               | 92                |
| Spare parts and laboratory materials | 211               | 169               |
| Water                                | 24                | 20                |
| Other materials                      | 301               | 356               |
| <b>Total:</b>                        | <b>13 543</b>     | <b>12 172</b>     |

| <b>Costs of external services</b>      | <b>01-12/2024</b> | <b>01-12/2023</b> |
|--|-------------------|-------------------|
|  | <i>BGN '000</i>   | <i>BGN '000</i>   |
| Security                               | 632               | 632               |
| Insurance                              | 30                | 24                |
| Telephone and postage expenses         | 32                | 35                |
| Equipment maintenance and subscription | 261               | 186               |
| Fees                                   | 325               | 285               |
| Transport costs                        | 48                | 64                |
| Other costs for external services      | 18 187            | 19 043            |
| <b>Total:</b>                          | <b>19 515</b>     | <b>2 0269</b>     |

| <b>Financial expenses</b>               | <b>01-12/2024</b> | <b>01-12/2023</b> |
|---|-------------------|-------------------|
|   | <i>BGN '000</i>   | <i>BGN '000</i>   |
| Interest expenses                       | 578               | 549               |
| Expenses from exchange rate differences | 135               | 83                |
| Other financial expenses                | 44                | 44                |
| <b>Total:</b>                           | <b>757</b>        | <b>676</b>        |

## Assets

|                                    | <b>01-12/2024</b> | <b>01-12/2023</b> |
|------------------------------------|-------------------|-------------------|
|                                    | <i>BGN '000</i>   | <i>BGN '000</i>   |
| <b>Non-current assets</b>          |                   |                   |
| Property, plant and equipment      | 34 465            | 33 083            |
| Intangible assets                  | 3 567             | 3 560             |
| Investments with minority interest | 69                | 19                |
| Trade receivables                  | 4 978             | 4 978             |
| <b>Total non-current assets</b>    | <b>43 079</b>     | <b>41 640</b>     |

**Current assets**

|                             |                |                |
|-----------------------------|----------------|----------------|
| Inventories                 | 15 862         | 14 303         |
| Trade and other receivables | 68 479         | 66 490         |
| Treasury shares redeemed    | -              | 12             |
| Cash and cash equivalents   | 79             | 60             |
| <b>Total current assets</b> | <b>84 420</b>  | <b>80 865</b>  |
| <b>Total Assets</b>         | <b>126 784</b> | <b>122 505</b> |

**01-12/2024** **01-12/2023**  
**BGN '000** **BGN '000**

**Property, plant and equipment**

|                               |               |               |
|-------------------------------|---------------|---------------|
| Land and buildings            | 23 880        | 23 954        |
| Machinery and equipment       | 9 167         | 9 045         |
| Other                         | 6             | 13            |
| In the process of acquisition | 283           | 71            |
|                               | <b>33 336</b> | <b>33 083</b> |

**Inventories**

**01-12/2024** **01-12/2023**  
**BGN '000** **BGN '000**

|               |               |               |
|---------------|---------------|---------------|
| Materials     | 14 318        | 13 103        |
| Production    | 265           | 423           |
| Goods         | 1 279         | 777           |
| <b>Total:</b> | <b>15 862</b> | <b>14 303</b> |

**Equity and liabilities**

**01-12/2024** **01-12/2023**  
**BGN '000** **BGN '000**

|                      |                |                |
|----------------------|----------------|----------------|
| Registered capital   | 91 800         | 84 500         |
| Statutory reserve    | 13 147         | 12 800         |
| Undistributed profit | 5 098          | 7 707          |
| <b>Total Equity</b>  | <b>110 045</b> | <b>105 007</b> |

**Liabilities**

**01-12/2024** **01-12/2023**  
**BGN '000** **BGN '000**

**Non-current liabilities**

|  |              |              |
|--|--------------|--------------|
| Long-term loans                        | 942          | 879          |
| Deferred tax liabilities               | 1 113        | 1 113        |
| Liabilities to employees on retirement | 173          | 197          |
| <b>Total non-current liabilities</b>   | <b>2 228</b> | <b>2 189</b> |

**Current liabilities**

|                                 |       |       |
|---------------------------------|-------|-------|
| Trade and other liabilities     | 4 201 | 4 768 |
| Short term loans                | 9 784 | 9 791 |
| Current part of long-term loans | 403   | 507   |

|                                     |                |                |
|-------------------------------------|----------------|----------------|
| Other tax liabilities               | 123            | 243            |
| <b>Total current liabilities</b>    | <b>14 511</b>  | <b>15 309</b>  |
| <b>Total liabilities</b>            | <b>16 739</b>  | <b>17 498</b>  |
| <b>Total equity and liabilities</b> | <b>126 784</b> | <b>122 505</b> |

## Financial indicators

01-12/2024 01-12/2023

|                          |      |      |
|--------------------------|------|------|
| Leverage ratio           | 0.15 | 0.17 |
| Financial autonomy ratio | 6.57 | 6.00 |

## Information on the shares of Tchaikapharma High Quality Medicines Inc.

The total amount of shares issued as of 31.12.2024 was 91,800,000 with a nominal value of BGN 1 per share. All issued shares are registered, dematerialized, ordinary and indivisible under the Statute of the Company. All issued shares are of the same type. Each share gives equal rights to its owner in proportion to the nominal value of the share. The shares of Tchaikapharma High Quality Medicines Inc. are traded on the official market of the Bulgarian Stock Exchange-Sofia.

## Essential information on the shares of Tchaikapharma High Quality Medicines Inc.

|   | 1-12/2024     | 1-12/2023     |
|---|---------------|---------------|
| Total number of issued shares                         | 91 800 000    | 84 500 000    |
| Number of shares in circulation at end of period      | 91 800 000    | 84 500 000    |
| Price per share at the end of the period in BGN       | 18.00         | 17.00         |
| Market capitalization at the end of the period in BGN | 1 652 400 000 | 1 436 500 000 |

Biser Georgiev

/Executive Director/